Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios Dimopoulos

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Leukemia|September 8, 2020
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapseMeletios Dimopoulos, Katja Weisel, Philippe Moreau, et al.
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
Blood|November 22, 2012
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myelomaAristeidis Chaidos, Chris P Barnes, Gillian Cowan, et al.
Cancer Treatment Reviews|September 25, 2010
Treatment of relapsed and refractory multiple myeloma in the era of novel agentsNiels W C J van de Donk, Henk M Lokhorst, Meletios Dimopoulos, et al.
Future Oncology (London, England)|July 29, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialAlessandra Tedeschi, Constantine S Tam, Roger G Owen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2018
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II TrialMeletios Dimopoulos, Katja Weisel, Niels W C J van de Donk, et al.
British Journal of Haematology|March 8, 2011
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trialPaul Richardson, Rudolf Schlag, Nuriet Khuageva, et al.
Blood|January 18, 2006
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemiaSteven P Treon, Morie A Gertz, Meletios Dimopoulos, et al.
Blood|February 5, 2011
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Nikhil C Munshi, Kenneth C Anderson, P Leif Bergsagel, et al.
Drugs|April 27, 2016
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in MyelomaPhilippe Moreau, Niels W C J van de Donk, Jesus San Miguel, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Leukemia|September 8, 2020
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapseMeletios Dimopoulos, Katja Weisel, Philippe Moreau, et al.
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
Blood|November 22, 2012
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myelomaAristeidis Chaidos, Chris P Barnes, Gillian Cowan, et al.
Cancer Treatment Reviews|September 25, 2010
Treatment of relapsed and refractory multiple myeloma in the era of novel agentsNiels W C J van de Donk, Henk M Lokhorst, Meletios Dimopoulos, et al.
Future Oncology (London, England)|July 29, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialAlessandra Tedeschi, Constantine S Tam, Roger G Owen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2018
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II TrialMeletios Dimopoulos, Katja Weisel, Niels W C J van de Donk, et al.
British Journal of Haematology|March 8, 2011
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trialPaul Richardson, Rudolf Schlag, Nuriet Khuageva, et al.
Blood|January 18, 2006
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemiaSteven P Treon, Morie A Gertz, Meletios Dimopoulos, et al.
Blood|February 5, 2011
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Nikhil C Munshi, Kenneth C Anderson, P Leif Bergsagel, et al.
Drugs|April 27, 2016
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in MyelomaPhilippe Moreau, Niels W C J van de Donk, Jesus San Miguel, et al.
Pageof 12